Fu-Rong You,
Fu-Rong You
Institution: NULL
Email:
Hui-Jun Lai,
Hui-Jun Lai
Institution: NULL
Email:
Lan Yang,
Lan Yang
Institution: NULL
Email:
Hong-Wei Guo
Hong-Wei Guo
Institution: NULL
Email:
3 weeks ago
Jacek Gronwald,
Jacek Gronwald
Institution: NULL
Email:
Cezary Cybulski,
Cezary Cybulski
Institution: NULL
Email:
Tomasz Huzarski,
Tomasz Huzarski
Institution: NULL
Email:
Anna Jakubowska,
Anna Jakubowska
Institution: NULL
Email:
Tadeusz Debniak,
Tadeusz Debniak
Institution: NULL
Email:
Marcin Lener,
Marcin Lener
Institution: NULL
Email:
Steven A Narod,
Steven A Narod
Institution: NULL
Email:
Jan Lubinski
Jan Lubinski
Institution: NULL
Email:
BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of three founder mutations. A rapid inexpensive tes...
More
BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of three founder mutations. A rapid inexpensive test for these three mutations can be used to screen all Polish adults at a reasonable cost. In the region of Pomerania of North-western Poland nearly half a million tests have been performed, in large part through engaging family doctors and providing ready access to testing through the Pomeranian Medical University. The following commentary provides a history of genetic testing for cancer in Pomerania and the current approach to facilitating access to genetic testing at the Cancer Family Clinic for all adults living in the region.
Less
3 weeks ago
Yue Yin Xia,
Yue Yin Xia
Institution: NULL
Email:
Joanne Kotsopoulos
Joanne Kotsopoulos
Institution: NULL
Email:
BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of use over ti...
More
BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of use over time have introduced lower hormonal dosages, different steroid types and non-oral routes of administration. Specifically, there has been a considerable shift in patterns of contraceptive use and the increase in the uptake of non-oral, long-acting, reversible contraception (e.g., intrauterine devices, implants, injections) has corresponded to a decline in oral contraceptive pill use. Whether or not these other methods confer a protective effect against ovarian cancer in the general population is not clear. To our knowledge, there have been no such studies conducted among BRCA mutation carriers. Furthermore, the impact of these changes on the risk of developing ovarian cancer is not known. In this article, we will review the existing epidemiologic evidence regarding the role of contraceptives and the risk of ovarian cancer with a focus on women with a BRCA1 or BRCA2 mutation. We will discuss recent findings and gaps in the knowledge while extrapolating from studies conducted among women from the noncarrier population.
Less
3 weeks ago
Tina Kamani,
Tina Kamani
Institution: NULL
Email:
Parsa Charkhchi,
Parsa Charkhchi
Institution: NULL
Email:
Afshan Zahedi,
Afshan Zahedi
Institution: NULL
Email:
Mohammad R. Akbari
Mohammad R. Akbari
Institution: NULL
Email:
Non-medullary thyroid cancer (NMTC) is the most common type of thyroid cancer. With the increasing incidence of NMTC in recent years, the familial form of the disease has also become more common than previously reported, accounting for 5–15% of NMTC cases. Familial NMTC is further classified as no...
More
Non-medullary thyroid cancer (NMTC) is the most common type of thyroid cancer. With the increasing incidence of NMTC in recent years, the familial form of the disease has also become more common than previously reported, accounting for 5–15% of NMTC cases. Familial NMTC is further classified as non-syndromic and the less common syndromic FNMTC. Although syndromic NMTC has well-known genetic risk factors, the gene(s) responsible for the vast majority of non-syndromic FNMTC cases are yet to be identified. To date, several candidate genes have been identified as susceptibility genes in hereditary NMTC. This review summarizes genetic predisposition to non-medullary thyroid cancer and expands on the role of genetic variants in thyroid cancer tumorigenesis and the level of penetrance of NMTC-susceptibility genes.
Less
3 weeks ago